Hamilton Lane Incorporated - Class A Common Stock (HLNE)
175.49
+2.89 (1.67%)
NASDAQ · Last Trade: May 28th, 5:51 PM EDT
Detailed Quote
Previous Close | 172.60 |
---|---|
Open | 172.62 |
Bid | 70.85 |
Ask | 194.58 |
Day's Range | 171.34 - 176.52 |
52 Week Range | 114.85 - 203.72 |
Volume | 1,622,200 |
Market Cap | - |
PE Ratio (TTM) | 44.09 |
EPS (TTM) | 4.0 |
Dividend & Yield | 1.960 (1.12%) |
1 Month Average Volume | 380,816 |
Chart
About Hamilton Lane Incorporated - Class A Common Stock (HLNE)
Hamilton Lane Inc is a leading investment management firm that specializes in private markets. The company offers a range of services, including advisory, investment management, and market research, tailored to meet the needs of institutional investors and clients seeking to access the private equity and alternative investment landscape. Hamilton Lane leverages its extensive expertise and proprietary technology to provide insights and strategies that help clients navigate complex investment opportunities while aiming to optimize returns and manage risks. The firm is dedicated to enhancing transparency and efficiency in private market investing through innovative solutions and strategic guidance. Read More
News & Press Releases
Hamilton Lane (NASDAQ:HLNE) excels as a quality investment with high ROIC, strong cash flow, and steady growth, making it a standout in private markets solutions.
Via Chartmill · May 27, 2025

Via Benzinga · February 5, 2025

Via Benzinga · January 13, 2025

Via Benzinga · December 27, 2024

Cosette Pharmaceuticals, Inc., a U.S.-based, fully integrated, pharmaceutical company, announced today that it has entered into a definitive agreement to acquire all the outstanding shares of Mayne Pharma Group Limited (ASX: Ticker MYX) (Mayne Pharma) at AUD$7.40/share for a total consideration of approximately USD $430 Million. The Boards of Directors of both companies have approved the transaction and Mayne Pharma’s Board of Directors has unanimously recommended that its shareholders vote in favor of the transaction. The transaction is expected to close in the second quarter of 2025.
By Cosette Pharmaceuticals, Inc. · Via Business Wire · February 20, 2025

Goldman Sachs predicts winners and losers among alternative asset managers, brokers, and traditional managers in 2025, with bold rating adjustments.
Via Benzinga · January 6, 2025

Via Benzinga · December 16, 2024

U.S. stocks advanced midday Tuesday, demonstrating resilience despite escalating geopolitical tensions and trade uncertainties between the world’s two largest economies.
Via Benzinga · February 4, 2025

Why Quality Investors May Find HAMILTON LANE INC-CLASS A (NASDAQ:HLNE) Attractive.
Via Chartmill · November 28, 2024

This article explores why quality investors may have a look at HAMILTON LANE INC-CLASS A (NASDAQ:HLNE)
Via Chartmill · November 5, 2024

Via Benzinga · October 22, 2024